Safety patterns with ozanimod during phase 3 and open-label extension trials in patients with relapsing multiple sclerosis

被引：0
|
作者：
Selmaj, K. W. [1 ,2 ]
Ziemssen, T. [3 ]
Comi, G. [4 ,5 ]
Hartung, H. -P. [6 ,7 ,8 ,9 ]
Singal, M. [10 ]
Riolo, J. V. [10 ]
Cheng, C. -Y. [10 ]
Sheffield, J. K. [10 ]
Minton, N. [10 ]
Vermersch, P. [11 ]
Cree, B. A. C. [12 ]
机构：
[1] Ctr Neurol, Lodz, Poland
[2] Univ Warmia & Mazury, Dept Neurol, Coll Medicum, Olsztyn, Poland
[3] Univ Hosp Dresden, Dept Neurol, Ctr Clin Neurosci, Carl Gustav Carus Univ Clin, Dresden, Germany
[4] Univ Vita Salute San Raffaele, Milan, Italy
[5] Casa Cura Policlin, Milan, Italy
[6] Heinrich Heine Univ, Med Fac, Dept Neurol, Dusseldorf, Germany
[7] Univ Sydney, Brain & Mind Ctr, Sydney, Australia
[8] Med Univ Vienna, Dept Neurol, Vienna, Australia
[9] Palacky Univ Olomouc, Olomouc, Czech Republic
[10] Bristol Myers Squibb, Princeton, NJ USA
[11] Univ Lille, Inserm UMR 1172, CHU Lille, FHU Precise, Lille, France
[12] Univ Calif San Francisco, Weill Inst Neurosci, Dept Neurol, San Francisco, CA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P732
引用
收藏
页码：641 / 642
页数：2
相关论文
共 50 条
  • [21] Safety of Evobrutinib in Patients With Relapsing Multiple Sclerosis is Maintained in a Long-term Open-label Extension of a Phase II Study
    Montalban, Xavier
    Arnold, Douglas L.
    Weber, Martin S.
    Staikov, Ivan
    Piasecka-Stryczynska, Karolina
    Martin, Emily C.
    Mandel, Matthew
    Zima, Yulia
    Shaw, Jamie
    Dangond, Fernando
    Grenningloh, Roland
    Li, Ying
    Tomic, Davorka
    Wolinsky, Jerry S.
    NEUROLOGY, 2021, 96 (15)
  • [22] Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial
    Naismith, Robert T.
    Cohen, Jeffrey A.
    Bar-Or, Amit
    Comi, Giancarlo
    Selmaj, Krzysztof W.
    Hartung, Hans-Peter
    Sheffield, James K.
    Krakovich, Anthony
    Tatosian, Daniel
    Cheng, Chun-Yen
    Reardon, Jennifer
    Khaychuk, Vadim
    Riolo, Jon, V
    Silva, Diego
    Cree, Bruce A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (02) : 177 - 183
  • [23] Update on Long-term Safety and Tolerability of Ozanimod by Age Category in Patients With Relapsing Multiple Sclerosis: Final Data From an Open-Label Extension Study
    Selmaj, Krzysztof
    Cohen, Jeffrey
    Steinman, Lawrence
    Comi, Giancarlo
    Bar-Or, Amit
    Hartung, Hans-Peter
    Montalban, Xavier
    Kappos, Ludwig
    Sheffield, James
    Cheng, Chun-Yen
    Riolo, Jon
    Krakovich, Anthony
    Cree, Bruce A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1017 - 1018
  • [24] Safety of Concurrent Administration of Serotonergic Antidepressants and Ozanimod in Participants With Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study
    Naismith, Robert
    Cohen, Jeffrey
    Bar-Or, Amit
    Comi, Giancarlo
    Selmaj, Krzysztof
    Hartung, Hans-Peter
    Sheffield, James
    Cheng, Chun-Yen
    Riolo, Jon
    Krakovich, Anthony
    Reardon, Jennifer
    Cree, Bruce A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1029 - 1030
  • [25] Safety of the bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis during an open-label extension to a phase ii study
    Montalban, X.
    Arnold, D. L.
    Weber, M.
    Staikov, I.
    Piasecka-Stryczynska, K.
    Martin, E.
    Mandel, M.
    Ona, V.
    Zima, Y.
    Tomic, D.
    Wolinsky, J.
    Dangond, F.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 233 - 233
  • [26] Correlations Between Early MRI Parameters and Long-term Clinical Outcomes in Phase 3 and Open-label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis
    Arnold, Douglas L.
    Freeman, Leorah
    Hartung, Hans-Peter
    Montalban, Xavier
    Cohen, Jeffrey A.
    Bar-Or, Amit
    Steinman, Lawrence
    DeLuca, John
    Cheng, Chun-Yen
    Riolo, Jon V.
    Silva, Diego
    Pachai, Chahin
    Cree, Bruce A. C.
    NEUROLOGY, 2023, 100 (17)
  • [27] Correlations between early MRI parameters and long-term clinical outcomes in phase 3 and open-label extension studies of ozanimod in relapsing multiple sclerosis
    Arnold, D. L.
    Freeman, L.
    Hartung, H. -P.
    Xavier Montalban, X.
    Cohen, J. A.
    Bar-Or, A.
    Steinman, L.
    DeLuca, J.
    Cheng, C. -Y.
    Riolo, J. V.
    Silva, D.
    Pachai, C.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 377 - 378
  • [28] Correlations Between Early MRI Parameters and Long-Term Clinical Outcomes in Phase 3 and Open-Label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study
    Arnold, Douglas
    Freeman, Leorah
    Hartung, Hans-Peter
    Montalban, Xavier
    Cohen, Jeffrey
    Bar-Or, Amit
    Steinman, Lawrence
    DeLuca, John
    Sheffield, James
    Cheng, Chun-Yen
    Riolo, Jon
    Pachai, Chahin
    Cree, Bruce A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1050 - 1051
  • [29] Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial
    Saida T.
    Kira J.-I.
    Kishida S.
    Yamamura T.
    Ohtsuka N.
    Ling Y.
    Torii S.
    Lucas N.
    Kuesters G.
    Steiner D.
    Tibung J.T.
    Neurology and Therapy, 2017, 6 (1) : 39 - 55
  • [30] Effect of ozanimod on circulating leukocyte subtypes: data from a randomised, open-label, phase 1 study in patients with relapsing multiple sclerosis
    Harris, S.
    Tran, J. Q.
    Cree, B. A. C.
    Southworth, H.
    Spencer, C. M.
    Zamvil, S. S.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 526 - 527
12345